GPR39 and carcinoma: In androgen-insensitive prostate cancer cell lines, ZnR/GPR39 activation by Zn2+ triggers PI3K pathway upregulation, which is reflected by increased expression and phosphorylation of AKT [84], associated with more malignant phenotypes of carcinomas [96,97,98].